Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)

Low-grade Gliomas Clinical Trial

Official title: Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)

Status Completed

Clinical Trial Summary

This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who have failed initial conventional treatment. In addition to evaluating the toxicity of this drug regimen, the potential efficacy of the regimen will be assessed.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioma
• Low-grade Gliomas
• Neurofibroma
• Neurofibromatoses
• Neurofibromatosis 1

• NCT number: NCT00901849
• Study type: Interventional
• Source: Children's Research Institute
• Status: Completed
• Phase: Phase 1
• Start date: May 2007
• Completion date: October 2012